Document Information [Table]
Document Information [Line Items]
Document Type
Document Type
Entity Registrant Name
Entity Registrant Name
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Ex Transition Period
Entity Central Index Key
Entity Central Index Key
Amendment Flag
Amendment Flag
Condensed Consolidated Balance Sheets
Assets, Current [Abstract]
CURRENT ASSETS:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Marketable Securities, Current
Marketable securities
Other Short-Term Investments
Strategic investments, current portion
Investments fair value
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable, net
Inventory, Net
Inventory
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Assets, Current
Total current assets
Property, Plant and Equipment, Net
Property and equipment, net
Total Property and equipment, net
Operating Lease, Right-of-Use Asset
Right-of-use assets
ROU Assets
Other Investments
Strategic investments, less current portion
Strategic investments
Represents the value of deposits and other assets.
Deposits And Other Assets
Deposits and other assets
Assets
TOTAL ASSETS
Liabilities, Current [Abstract]
CURRENT LIABILITIES:
Accounts Payable, Current
Accounts payable
Accrued Liabilities, Current
Accrued expenses and other liabilities
Total accrued expenses
Operating Lease, Liability, Current
Operating lease liability, current portion
Amount of warrant liability.
Warrant Liability
Warrant liability
Deferred Revenue, Current
Deferred revenue, current portion
Liabilities, Current
Total current liabilities
Deferred Revenue, Noncurrent
Deferred revenue, less current portion
Loans Payable, Noncurrent
Loan payable
Loan payable, less current portion
Operating Lease, Liability, Noncurrent
Operating lease liability, less current portion
Other Liabilities, Noncurrent
Other long-term liabilities
Liabilities
TOTAL LIABILITIES
Equity, Attributable to Parent [Abstract]
STOCKHOLDERS' EQUITY
Preferred Stock, Value, Issued
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized; none issued or outstanding at June 30, 2023 and December 31, 2022.
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized; none issued or outstanding at December 31, 2021 and December 31, 2022.
Common Stock, Value, Issued
Common stock, $0.0001 par value per share; 340,000,000 shares authorized; 35,743,007 and 20,187,850 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively.
Common stock, $0.0001 par value; 340,000,000 shares authorized; 8,822,280 and 20,187,850 shares issued and outstanding as of December 31, 2021 and December 31, 2022, respectively.
Additional Paid in Capital
Additional paid-in capital
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Equity, Including Portion Attributable to Noncontrolling Interest
Balance
Balance
TOTAL STOCKHOLDERS' EQUITY
Liabilities and Equity
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Preferred Stock, Par or Stated Value Per Share
Preference shares, par value (in Dollars per share)
Preferred Stock, Shares Authorized
Preference shares, shares authorized
Preferred Stock, Shares Issued
Preference shares, shares issued
Preferred Stock, Shares Outstanding
Preference shares, shares outstanding
Common Stock, Par or Stated Value Per Share
Common stock, par value (in Dollars per share)
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Outstanding
Total shares of Company Common Stock immediately after Business Combination
Common stock of HSAC2, outstanding prior to the Business Combination
Common stock, shares outstanding
Condensed Consolidated Statements of Operations and Comprehensive Loss
Statement [Table]
Product and Service [Axis]
Product and Service [Domain]
Partnership Revenue Member
Partnership revenue
Product [Member]
Product revenue
Statement [Line Items]
Revenues [Abstract]
Revenue:
Revenues
Revenue
Operating Expenses [Abstract]
Expenses:
Cost of Revenue
Cost of product revenues
Research and Development Expense
Research and development
Selling, General and Administrative Expense
Selling, general and administrative
Costs and Expenses
Total expenses
Operating Income (Loss)
Loss from operations
Nonoperating Income (Expense) [Abstract]
Other income (expense):
Interest Income (Expense), Net
Interest income (expense), net
Fair Value Adjustment of Warrants
Loss on fair value adjustment of warrant liability
Gain (loss) on fair value adjustment of warrant liability
Loss on fair value adjustment of warrant liability
(Gain) loss on fair value adjustment of warrant liability
Gain (Loss) on Extinguishment of Debt
Loss on debt extinguishment
Loss on extinguishment
Loss on debt extinguishment
Gain (Loss) on Investments
Loss (gain) on fair value of strategic investments
(Loss) gain on fair value of strategic investments
Other Operating Income (Expense), Net
Total other income (expense)
Net Income (Loss) Attributable to Parent
Net loss
Net loss
Net Loss Per Share
Net loss per share
Earnings Per Share, Basic
Basic (in Dollars per share)
Earnings Per Share, Diluted
Diluted (in Dollars per share)
Weighted Average Number of Shares Outstanding, Basic
Weighted-average shares used in computing net loss per share, basic (in Shares)
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average shares used in computing net loss per share, diluted (in Shares)
Comprehensive Loss Abstract
Comprehensive loss
Marketable Security, Unrealized Gain (Loss)
Unrealized loss on marketable securities
Unrealized gain (loss) on marketable securities
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Condensed Consolidated Statements of Stockholders Equity (Deficit)
Revision of Prior Period [Axis]
Revision of Prior Period [Domain]
Previously Reported
Previously Reported
Class of Stock [Axis]
Class of Stock [Domain]
Convertible Preferred Stock [Member]
Convertible Preferred Stock
Equity Components [Axis]
Equity Component [Domain]
Common Stock [Member]
Common Stock
Additional Paid-in Capital [Member]
Additional Paid-In Capital
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive (Loss)
Retained Earnings [Member]
Accumulated Deficit
Shares, Outstanding
Balance (in Shares)
Balance (in shares)
Amount of temporary equity retroactive of recapitalizations.
Temporary Equity Retroactive Application Of Recapitalizations
Retroactive application of reverse capitalization (Note 3)
Retroactive application of reverse capitalization
Temporary equity retroactive application of recapitalization of shares.
Temporary Equity Retroactive Application Of Recapitalization Shares
Retroactive application of reverse capitalization (Note 3) (in shares)
Retroactive application of reverse capitalization (in shares)
The quantified effect of merger and recapitalization on equity.
Effect Of Merger And Recapitalization
Effect of Merger and recapitalization (refer to Note 3)
Effect of Merger and recapitalization shares
Effect Of Merger And Recapitalization Shares
Effect of Merger and recapitalization (refer to Note 3) (in shares)
The amount of equity classified warrants.
Equity Classified Warrants
Reclassification of Legacy Orchestra common stock warrants to stockholders' equity
Equity impact of the value of stock issued for settlement of earnout during the period.
Stock Issued During Period, Value, Settlement of Earnout
Issuance of shares in settlement of earnout
Number of stock issued during the period in settlement of earnout.
Stock Issued During Period, Shares, Settlement of Earnout
Issuance of shares in settlement of earnout (in shares)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
Stock Issued During Period, Value, Stock Options Exercised
Exercise of stock options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercise of stock options (in shares)
Adjustments to Additional Paid in Capital, Warrant Issued
Exercise of warrants
Net amount of increase (decrease) in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
Adjustments To Additional Paid In Capital Warrant Issued Net
Exercise of warrants
Stock Issued During Period, Shares, New Issues
Exercise of warrants (in shares)
Shares issued (in shares)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
Forfeiture of restricted stock awards (in shares)
The amount of capital raised from the issuance of Preferred shares.
Capital Raised From The Issuance Of Preferred Shares
Proceeds from private placement financing
Proceeds From Issuance Of Shares Private Placement
Proceeds from private placement financing (in shares)
Stock Issued During Period, Value, Issued for Services
Shares issued pursuant to consulting agreement
Stock Issued During Period, Shares, Issued for Services
Shares issued pursuant to consulting agreement (in shares)
Stock Issued During Period Value Shares Issued In Settlement
Issuance of warrants pursuant to debt financing
Number of stock issued during the period in warrants pursuant to debt financing.
Stock Issued During Period, Shares, Warrants Pursuant to Debt Financing
Issuance of warrants pursuant to debt financing (in shares)
Adjustments to Additional Paid in Capital, Other
Other
Condensed Consolidated Statements of Cash Flows
Represents information pertaining to Series D-1 preferred stock.
Series D-1 Preferred Stock
Net Cash Provided by (Used in) Operating Activities [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, Depletion and Amortization
Depreciation and amortization
Amount of expense for award under share-based payment arrangement relating to consulting service.
Share Based Compensation Expense, Consulting Service
Shares issued as compensation for consulting services
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation
Accretion (Amortization) of Discounts and Premiums, Investments
Accretion and interest related to marketable securities
Operating Lease, Right-of-Use Asset, Periodic Reduction
Non-cash lease expense
Amortization of Debt Issuance Costs
Amortization of deferred financing fees
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable
Accounts receivable
Increase (Decrease) in Inventories
Inventory
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Accounts payable, accrued expenses and other liabilities
Increase (Decrease) in Operating Lease Liability
Operating lease liabilities - current and non-current
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Proceeds from Sale and Maturity of Marketable Securities
Sales of marketable securities
Payments to Acquire Marketable Securities
Purchases of marketable securities
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of Long-Term Debt
Repayment of debt financing, inclusive of debt extinguishment costs
Repayment of principal
Proceeds from Issuance of Debt
Proceeds from Avenue term loan
Proceeds from Warrant Exercises
Proceeds from exercise of warrants
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Effect of merger, net of transaction costs.
Effect Of Merger Net Of Transaction Costs
Effect of merger, net of transaction costs (Note 3)
Proceeds from Issuance of Preferred Stock and Preference Stock
Proceeds from private placement financing
Payments of Merger Related Costs, Financing Activities
Deferred financing, offering and merger costs
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Net (decrease) increase in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash and cash equivalents, end of the period
Cash and cash equivalents, beginning of the period
Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract]
Cash paid during the six months ended June 30:
Cash paid during the year for:
Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Interest
Noncash Investing and Financing Items [Abstract]
Non-cash financing activities:
Deferred offering and merger costs in accounts payable and accrued expenses.
Deferred Offering And Merger Costs In Accounts Payable And Accrued Expenses
Deferred offering and merger costs in accounts payable and accrued expenses
The value of warrants issued in exchange for the original debt being converted in a non cash (or part non cash) transaction.
Debt Conversion, Converted Instrument, Warrants Issued
Warrants issued pursuant to private placement financing
Warrants issued pursuant to Series D-2 Preferred Stock
Debt Conversion, Converted Instrument, Amount
Outstanding principal amount of the loans converted into common stock
Warrants issued pursuant to debt financing
Organization and Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Organization and Basis of Presentation
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Business Combination and Recapitalization
Business Combination Disclosure [Text Block]
Business Combination and Recapitalization
No definition available.
Terumo Agreement.
Terumo Agreement text block.
Terumo Agreement Text Block
Terumo Agreement
Medtronic Agreement
Medtronic Agreement Text Block
Medtronic Agreement
Financial Instruments and Fair Value Measurements
Fair Value Disclosures [Text Block]
Financial Instruments and Fair Value Measurements
Marketable Securities and Strategic Investments
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Marketable Securities and Strategic Investments
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Balance Sheet Components
Common and Preferred Stock
Equity [Text Block]
Common and Preferred Stock
Warrants
Disclosure of warrants.
Warrants Disclosure Text Block
Warrants
Share-Based Compensation
Share-Based Payment Arrangement [Text Block]
Stock-Based Compensation
Leases
Lessee, Operating Lease, Disclosure [Table Text Block]
Leases
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Debt Financing
Debt Disclosure [Text Block]
Debt Financing
Earnings Per Share [Text Block]
Net Loss Per Share
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
The entire disclosure of reverse recapitalization policy.
Reverse Recapitalization Policy Text Block
Reverse Recapitalization
Disclosure of accounting policy for emerging growth company and smaller reporting company status.
Emerging Growth Company Policy Text Block
Emerging Growth Company and Smaller Reporting Company Status
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Marketable Securities, Policy [Policy Text Block]
Marketable Securities
Investment, Policy [Policy Text Block]
Strategic Investments
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
Accounts Receivable [Policy Text Block]
Accounts Receivable and Allowance for Doubtful Accounts
Inventory, Policy [Policy Text Block]
Inventory
Research and Development Expense, Policy [Policy Text Block]
Research and Development Prepayments, Accruals and Related Expenses
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
Lessee, Leases [Policy Text Block]
Leases
Debt, Policy [Policy Text Block]
Debt Discount and Debt Issuance Costs
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets
The entire disclosure of warrants.
Warrants Policy Text Block
Warrants
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
The entire disclosure of product revenues policy.
Product Revenues Policy Text Block
Product Revenues
The entire disclosure of partnership revenue policy.
Partnership Revenue Policy Text Block
Partnership Revenues
Share-Based Payment Arrangement [Policy Text Block]
Stock-Based Compensation
Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share
Net Loss Per Share
Income Tax, Policy [Policy Text Block]
Income Taxes
Deferred Charges, Policy [Policy Text Block]
Deferred Offering and Merger Costs
The entire disclosure of defined contribution plan policy.
Defined Contribution Plan Policy Text Block
Defined Contribution Plan
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Loss
Segment Reporting, Policy [Policy Text Block]
Segment Reporting
New Accounting Pronouncements, Policy [Policy Text Block]
New Accounting Standards
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale useful lives.
Property Plant And Equipment Useful Lives Table Text Block
Schedule of property and equipment useful lives
Tabular disclosure of common stock following the consummation of business combination.
Schedule of Number of Shares of Common Stock after Business Combination [Table Text Block]
Schedule of common stock following the consummation of business combination
Tabular disclosure of reconciliation of business combination to statement of changes in stockholders equity.
Schedule of Reconciliation of Business Combination to Statement of Changes in Stockholders Equity [Table Text Block]
Schedule of reconciliation of business combination to statement of changes in stockholders equity
Deferred Income [Table Text Block]
Schedule of deferred revenue
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of financial assets and liabilities measured at fair value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of liabilities for which fair value is determined by Level 3
Marketable Securities [Table Text Block]
Schedule of marketable securities
Summary of the Company's marketable securities
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets.
Property Plant And Equipment Balances Table Text Block
Schedule of property and equipment, net
Schedule of property and equipment balances, net
Schedule of Accrued Liabilities [Table Text Block]
Schedule of accrued expenses
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Warrants
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of fair value of the outstanding warrant liability
Tabular disclosure of warrants activity.
Schedule of Warrants Activity [Table Text Block]
Schedule of warrant activity rollforward
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Schedule of purchase shares of Company Common Stock
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Schedule of cost related to stock-based compensation
Nonvested Restricted Stock Shares Activity [Table Text Block]
Schedule of restricted stock activity
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of estimated grant-date fair value calculated using Black-Scholes option pricing model
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of stock option activity
Tabular disclosure of the operating leases supplemental information.
Schedule Of Operating Leases Supplemental Information Table Text Block
Schedule of recognized as an asset and operating lease liabilities
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Schedule of future minimum rental payments, exclusive of taxes, insurance and other costs, under the leases
Schedule of Maturities of Long-Term Debt [Table Text Block]
Schedule of amount of principal payments
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of calculation of diluted net loss per share
Organization and Basis of Presentation (Details) [Table]
Business Combination, Separately Recognized Transactions [Axis]
Business Combination, Separately Recognized Transactions [Domain]
Business Combination Member
Business Combination [Member]
Business Combination
Organization and Basis of Presentation (Details) [Line Items]
Organization and Basis of Presentation
Summary of Significant Accounting Policies (Details) [Table]
Investment Objective [Axis]
Investment Objective [Domain]
Strategic Investments Less Current Portion
Counterparty Name [Axis]
Counterparty Name [Domain]
Terumo Agreement
Terumo Agreement
Summary of Significant Accounting Policies (Details) [Line Items]
Summary of Significant Accounting Policies
Accounts Receivable, Allowance for Credit Loss
Allowance for doubtful accounts receivable
Impairment, Long-Lived Asset, Held-for-Use
Impairment of long-lived assets
Term of billing from date of milestone achievement.
Term Of Billing From Date Of Milestone Achievement
Term of billing from date of milestone achievement
Term of royalty payments from close of each quarter.
Term Of Royalty Payments From Close Of Each Quarter
Term of royalty payments from close of each quarter
Term of optional services from receipt of invoice.
Term Of Optional Services From Receipt Of Invoice
Term of optional services from receipt of invoice
Term of SirolimusERF from receipt of shipping invoice.
Term Of Sirolimus E R F From Receipt Of Shipping Invoice
Term of SirolimusERF from receipt of shipping invoice
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Income tax benefit percentage
Income tax benefit at federal statutory rate
Deferred Offering Costs
Deferred offering deposit
Deferred offering cost
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay
Defined contribution plan, percentage
Defined Contribution Plan, Cost
Contribution
Number of Operating Segments
Number of operating segments
Property, Plant and Equipment [Table]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset [Domain]
Manufacturing Equipment Member
Office furniture
Research And Development Equipment Member
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Minimum
Minimum
Maximum
Maximum
Property, Plant and Equipment
Schedule of Property and Equipment, Net
Balance Sheet Components
Property, Plant and Equipment, Useful Life
Total asset category
Schedule of Business Acquisitions, by Acquisition [Table]
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Represents information pertaining to Health Sciences Acquisitions Corporation 2.
HSAC2
HSAC2
Legal Entity [Axis]
Entity [Domain]
Represents information pertaining to HSAC 2 Holdings, LLC.
HSAC 2 Holdings, LLC
HSAC 2 Holdings, LLC
Scenario [Axis]
Scenario [Domain]
Represents the scenario of initial milestone event.
Initial milestone event
Initial milestone event
Represents the scenario of final milestone event.
Final milestone event
Final milestone event
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Represents information pertaining to private warrants.
Private warrants
Private warrants
Represents information pertaining to RTW Investments, LP and Covidien Group S..r.l.
RTW Funds and Covidien Group
Represents information pertaining to Medtronic plc.
Medtronic
Represents information pertaining to RTW Investments, LP.
RTW Funds
Sale of Stock [Axis]
Sale of Stock [Domain]
Represents information pertaining to forward purchase agreement.
Forward purchase agreement
Represents information pertaining to backstop agreement.
Backstop agreement
Business Acquisition [Line Items]
Business Combination and Recapitalization
The maximum number of shares permitted to be issued by an entity's charter and bylaws.
Shares Authorized
Shares authorized (in shares)
Goodwill
Goodwill
Intangible Assets, Net (Excluding Goodwill)
Intangible assets
Percent of shares forfeited by the sponsor.
Sponsor, Shares Forfeiture, Percent
Sponsor share forfeiture (as percent)
Number of shares forfeited by the sponsor.
Sponsor, Shares Forfeiture, Number
Number of shares forfeiture by sponsor
Price of the entity's common stock which would be required to be attained for the forfeiture of sponsor shares to become effective.
Sponsor, Shares Forfeiture, Stock Price Trigger
Sponsor share forfeiture, stock price trigger
Threshold number of specified trading days that common stock price must exceed threshold percentage within a specified consecutive trading period to trigger forfeiture of sponsor shares.
Sponsor, Shares Forfeiture, Threshold Trading Days
Sponsor share forfeiture, threshold trading days
Threshold period of specified consecutive trading days within which common stock price must exceed threshold percentage for specified number of trading days to trigger forfeiture of sponsor shares.
Sponsor, Shares Forfeiture, Threshold Consecutive Trading Days
Sponsor share forfeiture, threshold consecutive trading days
Number of insider shares subject to lock up period.
Shares Subject to Lock Up Period, Insider Shares
Insider shares subject to lock up period
Number of private shares subject to lock up period.
Shares Subject to Lock Up Period, Private Shares
Private shares subject to lock up period
The lock up period of shares.
Shares Lock Up Period
Share lock up period
Percent of warrants forfeited by the sponsor.
Sponsor, Warrants Forfeiture, Percent
Sponsor warrant forfeiture (as percent)
Class of Warrant or Right, Outstanding
Warrants closing balance
Warrants beginning balance (Number)
Warrants
Warrants outstanding (in shares)
Number of warrants forfeited by the sponsor.
Sponsor, Warrants Forfeiture, Number
Number of warrants forfeiture by sponsor
The amount of consideration for forfeiture of warrants.
Sponsor, Warrants Forfeiture, Consideration
Consideration for forfeiture of warrants
Number of warrants issued during the period.
Class of Warrant or Right, Number of Warrants Issued
Number of warrants issued
The number of employees and directors to whom warrants are issued.
Warrants Issued, Number of Employees and Directors
Number of employees and directors, warrants issued
The exercisable term of warrants.
Warrants and Rights Outstanding, Exercisable Term
Warrants exercisable term
Number of shares of equity interests issued or issuable as earnout consideration in a business combination.
Business Acquisition, Earnout Consideration, Equity Interest Issued or Issuable, Number of Shares
Number of shares issuable as earnout consideration
The number of shares of equity interests issued as earn-out consideration in a business combination, after rounding.
Business Acquisition, Earn-out Consideration, Equity Interests, Number of Shares Issued After Rounding
Number of shares issuable as earnout consideration due to rounding
Percent of shareholders elected to participate in earnout.
Percent of Shareholders Elected to Participate in Earnout
Percent of shareholders elected to participate in earnout
The aggregate amount of shares to be issued.
Shares Offering, Aggregate Amount
Aggregate amount of shares to be issued
Stock Issued During Period, Value, New Issues
Value of shares issued
Shares Issued, Price Per Share
Share issue price (in dollars per share)
The threshold amount of remaining cash in working capital and trust account for issue of shares.
Threshold Cash Remaining at Working Capital and Trust Account for Share Issue
Threshold remaining working capital and trust account for share issue
Represents information pertaining to Legacy Orchestra.
Legacy Orchestra Member
Legacy Orchestra
Stock Redeemed or Called During Period, Shares
Less: Redemption of HSAC2 shares
Number of shares of common stock outstanding after redemption.
Common Stock, Shares, Outstanding, after Redemption
Common stock held by former HSAC2 shareholders
Number of shares issued to sponsor and other initial shareholders.
Stock Issued to Sponsor and Other Initial Shareholders
HSAC2 sponsor shares
Number of shares of common stock outstanding prior to merger consideration.
Common Stock, Shares, Outstanding, Prior to Merger Consideration
Total shares outstanding prior to issuance of merger consideration to Legacy Orchestra stockholders
Number of shares of stock issued during the period pursuant to recapitalization.
Stock Issued During Period, Shares, Recapitalization
Shares issued to Legacy Orchestra stockholders - Company Common Stock
The amount of cash acquired through reverse recapitalization.
Cash Acquired Through Reverse Recapitalization
Cash - HSAC2's trust (net of redemption)
Proceeds from Issuance of Private Placement
Cash - Backstop Agreement
Proceeds from private placement financing
The cash inflow from reverse recapitalization before payment of transaction costs.
Proceeds from Reverse Recapitalization, before Transaction Costs
Gross proceeds
The cash inflow from reverse recapitalization after payment of transaction costs.
Proceeds from Reverse Recapitalization, after Transaction Costs
Effect of Business Combination, net of redemptions and transaction costs
The cash inflow issuance of stock from reverse recapitalization.
Proceeds from Issuance of Stock, Reverse Recapitalization
Proceeds from reverse recapitalization
Business Acquisition, Transaction Costs
Transaction costs
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement
Represents information relating to Terumo.
Terumo
Terumo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Terumo Agreement
Amount of cash inflow from upfront payment received or receivable pursuant to the agreement.
Collaborative Arrangement, Upfront Payment
Upfront payment received
Amount of cash inflow from equity commitment received or receivable pursuant to the agreement.
Collaborative Arrangement, Equity Commitment
Equity commitment
Amount invested in financing pursuant to the agreement.
Collaborative Arrangement, Payment for Financing
Amount invested for financing
Amount of receivable from additional payments based on the achievement of certain development and regulatory milestones pursuant to the agreement.
Collaborative Arrangement, Additional Amount Receivable on Achievement of Milestones
Additional payments on the achievement milestone
Percentage of royalty receivable at a rate based on Future Sale.
Collaborative Arrangement, Royalty Rate on Future Sale
Royalty receivable percentage
Amount of receivable from payments based on achievement of certain milestones with specified achievement dates.
Collaborative Arrangement, Amount Receivable on Milestones With Specified Achievement Dates
Amount receivable on Milestones
Amount of target achievement date for milestone payments passed.
Collaborative Arrangement, Milestone Payment Amount, Target Achievement Dates Passed
Target milestone payment date already passed
Amount of remaining time-based milestones by the specified target achievement dates probable of not achieving.
Collaborative Arrangement, Remaining Time Based Milestones Probable of Not Achieving by Specified Target Date
Remaining time-based milestones by the specified target achievement
Amount of total cash inflow from stock purchase and the revenue generating elements pursuant to the agreement.
Collaborative Arrangement, Proceeds From Stock Purchase And Revenue
Stock purchase and the revenue generating elements
Amount of fair value of shares recorded from agreement.
Collaborative Arrangement, Shares Fair Value
Estimated fair value of the shares
Amount of transaction price recorded from agreement.
Collaborative Arrangement, Transaction Price
Transaction price
Percentage of sales-based royalties on product sales by Terumo subsequent to commercialization.
Collaborative Arrangement, Sales Based Royalties Percentage
Sales-based royalties percentage
Change in Contract with Customer, Liability [Abstract]
Changes in the Company's deferred revenue balance
Contract with Customer, Liability
Deferred Revenue - June 30, 2023
Deferred Revenue - December 31, 2022 (in thousands)
Contract with Customer, Liability, Revenue Recognized
Revenue recognized
Revenue recognized
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
Revenue, Remaining Performance Obligation, Amount
Revenue remaining performance obligation amount
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Remaining performance obligation recognition period
Amount of cost incurred for the agreement.
Collaborative Arrangement, Cost Incurred
Cost incurred
Percentage of increase (decrease) in estimated total cost.
Collaborative Arrangement, Estimated Total Cost Increase (Decrease), Percentage
Estimated total costs increase (decrease) percentage
Amount of increase (decrease) in revenue from change in estimate.
Collaborative Arrangement, Change in Estimate, Increase (Decrease) in Revenue
Increase (decrease) in revenue from change in estimate
Represents increase (decrease) in basic earnings per share from change in estimate.
Collaborative Arrangement, Change in Estimate, Increase (Decrease) in Earnings Per Share, Basic
Collaborative Arrangement, Change in Estimate, Increase (Decrease) in Earnings Per Share , Basic
Represents increase (decrease) in diluted earnings per share from change in estimate.
Collaborative Arrangement, Change in Estimate, Increase (Decrease) in Earnings Per Share, Diluted
Collaborative Arrangement, Change in Estimate, Increase (Decrease) in Earnings Per Share
Medtronic Agreement (Details) [Table]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Accounts Payable and Accrued Expenses
Medtronic Agreement [Member]
Medtronic Agreement
Medtronic Agreement (Details) [Line Items]
Medtronic agreement
Expected revenue amount per unit.
Estimated Future Product Price
Expected to receive product price
The amount of reimbursable research and development expense.
Reimbursable Research And Development Expense
Reimbursable research and development expense
Proceeds from Issuance or Sale of Equity
Proceeds from issuance of Series D-2 Preferred Stock
The amount of revenue recognized to date under agreement.
Revenue Recognized To Date
Revenue recognized to date
Financial Instruments and Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value [Table]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Level 1
Fair Value, Inputs, Level 2 [Member]
Level 2
Fair Value, Inputs, Level 3 [Member]
Level 3
Financial Instrument [Axis]
Financial Instruments [Domain]
Money market fund
Investment in Motus GI
Debt and government securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.
Marketable securities (Corporate and Government debt securities)
Warrant liability.
Warrant
Schedule of Financial Assets and Liabilities Measured at Fair Value [Abstract]
Financial assets and liabilities measured at fair value
Fair value portion of probable future economic benefits obtained
or controlled by an entity as a result of past transactions or
events including money market fund.
Assets Fair Value Including Money Market Fund Disclosure
Total assets
Liabilities, Fair Value Disclosure
Total liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Liability Class [Axis]
Fair Value by Liability Class [Domain]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Rollforward
Financial Instruments and Fair Value Measurements
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Roll-forward of liabilities determined by Level 3 inputs
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Balance - ending
Balance - beginning
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Warrants exercised prior to the Business Combination
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Change in fair value of warrants
Amount of liability reclassified to equity from liability measured at fair value on recurring basis using unobservable input (level 3).
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassified To Equity
Warrants reclassified to equity
Marketable Securities and Strategic Investments (Details) [Table]
Represents Haemonetics Corporation.
Haemonetics Corporation
Strategic Investment Motus GI
strategic Investment Vivasure Member
Strategic Investment Vivasure
Marketable Securities and Strategic Investments (Details) [Line Items]
Marketable Securities and Strategic Investments
Debt Securities, Available-for-Sale, Realized Gain (Loss)
Recognized gains (loss)
Amount of realized and unrealized gain (loss) on investment.
Gain Loss On Investment
Investments gain
Asset Impairment Charges
Impairment charge
Marketable Securities [Table]
Corporate debt securities
Government debt securities
Schedule of Marketable Securities [Abstract]
Marketable Securities
Marketable Securities and Strategic Investments
Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss
Amortized Cost Basis
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Unrealized Losses
Debt Securities, Available-for-Sale
Fair Value
Marketable securities held
Depreciation
Depreciation and amortization expense
Equipment
Leasehold Improvements
Construction in Progress [Member]
Construction in progress
Property, Plant and Equipment, Gross
Property and equipment, gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less accumulated depreciation and amortization
Employee-related Liabilities, Current
Accrued compensation
Clinical Trial Accruals
Clinical trial accruals
Other Accrued Liabilities, Current
Other accrued expenses
Schedule of Stock by Class [Table]
Series D preferred stock
Class of Stock [Line Items]
Preferred Stock
Common and Preferred Stock
Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Common Stock
Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Preferred Stock
Represents information pertaining to Private Warrants Held By Sponsor.
Private Warrants Held by Sponsor
Private Warrants Held by Sponsor
Class of Warrant or Right, Exercise Price of Warrants or Rights
Price per share (in dollars per share)
Exercise Price
Share Price
Share price
Fair value of common stock
Warrants and Rights Outstanding, Term
Warrants expiry term
Term
Represents information relating to Legacy Orchestra Warrants.
Legacy Orchestra Warrants Member
Legacy Orchestra Warrants
Represents information relating to Legacy Orchestra Preferred Warrants.
Preferred Warrants
Preferred Warrants
Represents information relating to Legacy Orchestra Common Warrants.
Commons Warrants
Commons Warrants
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Expected volatility
Expected volatility
Risk-free interest rate
Risk-free interest rate
Remaining Term (in Years)
Remaining Term (in Years)
Exercise price
Exercise price
Fair value of common stock
Stock price
Expected dividend yield
Expected dividend yield
Fair value portion of warrant liabilities.
Warrant Liability, Fair Value Disclosure
Warrant liability, Fair value
Warrants and Rights Outstanding, Measurement Input
Warrants, measurement input
Number of warrants exercised during the period.
Warrants Exercised, Number
Exercise of warrants
The number of forfeiture of warrants.
Forfeiture Of Warrants, Number
Forfeiture of warrants
Number of warrants forfeited
The number of issuance of warrants related to Legacy Orchestra preferred stock financing.
Issuance Of Warrants Related To Legacy Orchestra Preferred Stock Financing, Number
Issuance of warrants related to Legacy Orchestra preferred stock financing
The number of issuance to amendments of existing warrants.
Amendments Of Existing Warrants, Number
Amendments of existing warrants
The number of warrants other.
Warrants Other, Number
Other
Number of warrants reclassified to equity during the period.
Warrants Reclassified to Equity, Number
Warrants reclassified to equity
Warrants and Rights Outstanding
Warrants closing balance
Warrants beginning balance (Amount)
Value of warrants exercised during the period.
Warrants Exercise During Period, Value
Warrants exercised (Amount)
The value of forfeiture of warrants.
Forfeiture Of Warrants, Value
Forfeiture of warrants (Amount)
The value of issuance of warrants related to Legacy Orchestra preferred stock financing.
Issuance Of Warrants Related To Legacy Orchestra Preferred Stock Financing, Value
Issuance of warrants related to Legacy Orchestra preferred stock financing (Amount)
The value of amendments of existing warrants.
Amendments Of Existing Warrants, Value
Amendments of existing warrants (Amount)
The value of warrants other.
Warrants Other, Value
Other (Amount)
Amount of expense (income) related to adjustments to fair value of warrant liability.
Fair Value Adjustments Of Warrants
Change in the fair value of warrants
Change in the fair value of warrants (Amounts)
Amount of increase in additional paid in capital (APIC) resulting from the reclassification of warrants to equity.
Adjustments to Additional Paid in Capital, Warrant Reclassified to Equity
Warrants reclassified to equity
Represents information relating to Liability-classified Warrants.
Liability-classified Warrants
Represents information relating to Legacy Orchestra Liability classified Warrants.
Legacy Orchestra Warrants
Legacy Orchestra Warrants
Represents information relating to Equity-classified Warrants.
Equity-classified Warrants
Equity-classified Warrants
Represents information relating to Legacy Orchestra Equity classified Warrants.
Legacy Orchestra Warrants.
Legacy Orchestra Warrants
Represents information relating to Private Warrants Held by Employees.
Private Warrants Held by Employees
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Plan Name [Axis]
Plan Name [Domain]
Represents the information pertaining to 2018 Equity Incentive Plan.
2018 Plan
2018 Plan
Represents the information pertaining to 2023 Equity Incentive Plan.
2023 Plan
2023 Plan
Represents the information pertaining to Orchestra BioMed, Inc.
Legacy Orchestra
Legacy Orchestra
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-Based Compensation
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of shares authorized
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Expiration period (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum
Percentage of shares outstanding
Common Stock, Capital Shares Reserved for Future Issuance
Shares available for future issuance
Number of new shares reserved for issuance of options and warrants
Award Type [Axis]
Award Type [Domain]
Stock options
Stock option
Unvested Restricted Stock Awards
Restricted Stock
Income Statement Location [Axis]
Income Statement Location [Domain]
Research and development
Selling, general and administrative
Share-Based Payment Arrangement, Expense
Total stock-based compensation
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Unrecognized stock-based compensation expense for options
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Expected period to be recognized
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of warrants to be issued
Number of shares of common stock called by warrants issued
Represents the information pertaining to 2018 and 2023 Equity Incentive Plan.
2018 and 2023 Plan
Retroactive application of Reverse Recapitalization
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Shares Underlying Options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Restricted Stock Outstanding, Ending
Restricted Stock Outstanding, Beginning
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Restricted Stock Outstanding, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Restricted Stock Outstanding, Forfeited/canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Shares Underlying Options, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding June 30, 2023
Weighted Average Exercise Price Outstanding, Beginning at January 1, 2023
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted Average Exercise Price, Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted Average Exercise Price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted Average Exercise Price, Forfeited/canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted Average Exercise Price, Exercisable at June 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Term (years) and Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted Average Remaining Term (years), Outstanding June 30, 2023
Weighted Average Remaining Term (years), Outstanding January 1, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted Average Remaining Term (years), Exercisable at June 30, 2023
Weighted Average Remaining Term (years), Exercisable at December 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate Intrinsic Value Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate Intrinsic Value, Exercisable at June 30, 2023
Aggregate Intrinsic Value, Exercisable at December 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Restricted Stock Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Shares Underlying Options, Outstanding June 30, 2023
Shares Underlying Options Outstanding, Beginning at January 1, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Shares Underlying Options, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Forfeited/canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms
Weighted Average Remaining Term (years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Restricted Stock Vested, weighted-average grant date fair
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Leases (Details) [Table]
Leases (Details) [Line Items]
Leases
Area of Real Estate Property
Lease space
Operating Leases, Rent Expense
Rent lease expense
The monthly amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Monthly Lease And Rental Expense
Monthly rent expense
Operating Lease Right Of Use Assets
Operating lease liabilities
Operating Lease, Payments
Cash paid for operating lease liabilities
Operating Lease, Weighted Average Remaining Lease Term
Weighted average remaining lease term - operating leases, in years
Operating Lease, Weighted Average Discount Rate, Percent
Weighted average discount rate - operating leases
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating Lease Maturity
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2023 (remaining six months)
Lessee, Operating Lease, Liability, to be Paid, Year One
2024
2023
Lessee, Operating Lease, Liability, to be Paid, Year Two
2025
2024
Lessee, Operating Lease, Liability, to be Paid, Year Three
2026
2025
Lessee, Operating Lease, Liability, to be Paid, Year Four
2027
2026
Lessee, Operating Lease, Liability, to be Paid, Year Five
2028
2027
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Lessee Operating Lease Liability Payments Due After Year Four
Thereafter
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Thereafter
Lessee, Operating Lease, Liability, to be Paid
Total future minimum lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Imputed interest
Operating Lease, Liability
Lease liabilities
Total liability
Lease Liabilities
Schedule of Related Party Transactions, by Related Party [Table]
Related Party, Type [Axis]
Related Party, Type [Domain]
Represents information of Vivasure.
Vivasure
Vivasure
Related Party Transaction [Line Items]
Related Party Transaction
The amount of unsecured convertible redeemable notes receivable contributions.
Unsecured Convertible Redeemable Note Receivable Contributions
Unsecured convertible redeemable notes
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Represents the information pertaining to 2022 Loan and Security Agreement.
2022 Loan and Security Agreement
2022 Loan and Security Agreement
Represents the information pertaining to Tranche one of 2022 Loan and Security Agreement.
Tranche One
Tranche One
Represents the information pertaining to Tranche two of 2022 Loan and Security Agreement.
Tranche Two
Tranche Two
Represents the information pertaining to Tranche three of 2022 Loan and Security Agreement.
Two Thousand Twenty Two Loan and Security Agreement Tranche Three [Member]
Tranche Three
Represents the information pertaining to 2019 Loan and Security Agreement.
2019 Loan and Security Agreement
2019 Loan and Security Agreement
Represents the information pertaining to Fund I and II warrants.
Fund I and II warrants
Fund I and II warrants
Variable Rate [Axis]
Variable Rate [Domain]
Prime rate
Prime rate
Debt Instrument [Line Items]
Debt Financing
Debt Instrument, Face Amount
Term loan
Debt instrument, face value
Number of tranches in debt instrument.
Debt Instrument, Number of Tranches
Number of tranches
Debt Instrument, Convertible, Conversion Price
Conversion price
Term of conversion option not exercised by lender during the six month period after completion of the Business Combination.
Debt Instrument, Conversion Option Not Exercisable Term
Conversion option not exercisable term
Number of warrants exercisable for shares of common stock.
Warrants Exercisable for Shares of Common Stock
Opportunities Fund I and II warrants
The estimated fair value of warrants as at the end of the reporting period.
Estimated Fair Value of Warrants
Estimated fair value of the warrants
The accumulated amount of other financing cost in a debt instrument.
Debt Instrument, Other Financing Cost
Other financing cost
Debt Instrument, Basis Spread on Variable Rate
Interest rate variable (as a percent)
Debt Instrument, Interest Rate, Effective Percentage
Interest rate
Debt Instrument, Term
Repayment terms of the loan
Term of repayment of interest alone in a debt instrument.
Debt Instrument Repayment of Interest Only Term
Repayment of interest only term
Debt Instrument, Periodic Payment, Principal
Repayment of principal
Percentage of initial commitment amount in a debt instrument.
Debt Instrument, Percentage of Initial Commitment Amount
Percentage of initial commitment amount
The amount of initial commitment amount in debt instrument.
Debt Instrument, Initial Commitment Amount
Initial commitment amount
Percentage of warrants on amount drawn.
Percentage of Warrants on Amount Drawn
Percentage of amount drawn
Number of warrants issued during period.
Warrant Issued
Warrants Issued
Debt Instrument, Interest Rate, Stated Percentage
Interest rate stated (as a percent)
Percentage of original principal amount od debt.
Debt Instrument, Percentage of Original Principal Amount
Percentage of original aggregate principal amount
Interest Expense, Debt
Interest expense
Long-Term Debt, Fiscal Year Maturity [Abstract]
Debt Maturity
Long-Term Debt, Maturity, Year One
2024
Long-Term Debt, Maturity, Year Two
2025
Long-Term Debt, Maturity, Year Three
2026
Long-Term Debt
Total
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Conversion Option
Represents forfeitable shares.
Forfeitable Shares
Represents earnout consideration.
Earnout Consideration
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities
Shares Consideration
Shares consideration
Number of shares earnout first milestone.
Earnout First Milestone
Earnout first milestone
The number of earn-out shares in first milestone after rounding off.
Earn-Out Shares, First Milestone, Rounded Off
Earnout first milestone Round off
Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends
Forfeitable shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities
Subsequent Events Details [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent events
Subsequent Events (Details) [Line Items]
Subsequent Events
Amount of cash payment due with respect to certain fees under the debt arrangement.
Debt Instrument, Cash Payment Due With Respect To Certain Fees
Cash payment due with respect to certain fees
Amount of cash outflow for payment of net interest, prepayment fees and legal fees.
Payment Of Net Interest, Prepayment Fees And Legal Fees
Payment of net interest, prepayment fees, and legal fees
Loans Payable, Current
Loan payable, current portion
Net Income (Loss) Available to Common Stockholders, Basic
Net loss attributable to common shareholders
It represents amount of deferred rent on operating activities
Deferred Rent On Operating Activities
Deferred rent
Interest and Dividend Income, Securities, Operating
Accretion and interest related to marketable securities
The cash outflow from purchase of related party convertible notes.
Payments for Purchase of Related Party Convertible Notes
Purchases of related party convertible notes
The cash outflow from purchase of strategic investment.
Payments for Purchase of Strategic Investment
Purchases of strategic investments
Payments for Repurchase of Warrants
Warrant repurchases
Represents warrants issued pursuant to private placement financing in a non cash investing and financing activity.
Warrants Issued Pursuant to Private Placement Financing
Warrants issued pursuant to private placement financing
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Accounting Standards Update and Change in Accounting Principle [Table]
Accounting Standards Update [Axis]
Accounting Standards Update [Domain]
Accounting Standards Update 2016-02 [Member]
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Summary of Significant Accounting Policies
Accounting Standards Update and Change in Accounting Principle [Table Text Block]
Schedule of effect of the transition adjustment along with balances before, and after adoption
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of components of the deferred tax assets and liabilities
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule of reconciliation of the statutory federal income tax to the Company's effective tax
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Schedule of reconciliation of total amounts of gross unrecognized tax benefits
FreeHold Surgical, Inc [Member]
Free Hold Surgical Inc Member
FreeHold Surgical, Inc [Member]
FreeHold Surgical, Inc
Revenue from Contract with Customer, Excluding Assessed Tax
Revenue
Cumulative Effect, Period of Adoption [Axis]
Cumulative Effect, Period of Adoption [Domain]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Adjusted balance
The amount of deferred lease liabilities.
Deferred Lease Liabilities
Deferred lease liability
Amount of revenue reduced that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
Contract With Customer Liability Revenue Reduced
Revenue reduction
Assets, Fair Value Disclosure
Total assets
Marketable Securities
Marketable securities
Amount of offering costs and merger costs as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
Deferred Offering And Merger Costs Current
Deferred offering and merger costs
Amount of deferred lease liabilities as of the balance sheet date capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
Deferred Lease Liabilities Current
Deferred lease liability
The amount of additional expense on amendment of existing warrants.
Additional Expense on Amendment of Existing Warrants
Additional expense on amendment
Preferred Stock [Member]
Preferred Stock
Number of warrants reduced due to reclassification of warrant liability upon exercise.
Reclassification of Warrant liability upon Exercise, Number
Reclassification of warrant liability upon exercise
Number of warrants issued related to preferred stock financing.
Issuance Of Warrants Related To Preferred Stock Financing, Number
Issuance of warrants related to preferred stock financing
Value reduced due to reclassification of warrant liability upon exercise.
Reclassification of Warrant liability upon Exercise
Reclassification of warrant liability upon exercise (Amount)
The value of issuance of warrants related to preferred stock financing.
Issuance Of Warrants Related To Preferred Stock Financing
Issuance of warrants related to preferred stock financing (Amount)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted, weighted-average grant date fair value
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Granted
Weighted Average Remaining Term (years)
Deferred tax assets
Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Net operating loss carryovers - Federal
Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Net operating loss carryovers - State
Deferred Tax Asset, Debt Securities, Trading, Unrealized Loss
Unrealized loss on equity securities
Deferred Tax Assets, Tax Credit Carryforwards, Research
Research and development credits
Federal research and development tax credits
Deferred Tax Assets, Investments
Loss on impairment of strategic investments
Deferred Tax Assets, in Process Research and Development
Research and experimental costs
Deferred Tax Assets, Other
Other
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.
Deferred Tax Assets, Lease Liabilities
Lease liability
Deferred Tax Assets, Deferred Income
Deferred revenue
Deferred Tax Assets, Gross
Total deferred tax assets
Deferred Tax Assets, Valuation Allowance
Less: valuation allowance
Deferred Tax Assets, Net of Valuation Allowance
Total deferred tax assets
Deferred tax liabilities
Amount of deferred tax liability attributable to taxable temporary differences from ROU Assets.
Deferred Tax Liabilities, Right of Use Assets
Right-of-use asset
Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization.
Deferred Tax Liabilities, Depreciation and Amortization
Depreciation and amortization
Deferred Income Tax Liabilities, Net
Total deferred tax liabilities
Deferred Tax Assets, Net
Total net deferred tax asset
Reconciliation of the statutory federal income tax to the Company's effective tax
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State and local income tax (net of Federal benefit)
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.
Effective Income Tax Rate Reconciliation, Permanent Items, Percent
Permanent items
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Research and development credits
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions relating to research and development expense.
Effective Income Tax Rate Reconciliation, Research and Development, Uncertain Tax Positions, Percent
Research and development, uncertain tax positions
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
Effect of rate changes
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true ups.
Effective Income Tax Rate Reconciliation, True Ups, Percent
True-ups
Effective Income Tax Rate Reconciliation, Percent
Effective tax rate
Changes in unrecognized tax benefits
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
Unrecognized tax benefits at the end of the period
Unrecognized tax benefits at the beginning of the period
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Additions due to current year activity
Amount of decrease in unrecognized tax benefits resulting from other reductions.
Unrecognized Tax Benefits, Decrease from Other Reductions
Other reductions
Schedule of information pertaining to incomes taxes.
Income Tax Disclosure [Table]
Income Tax Authority [Axis]
Income Tax Authority [Domain]
Domestic Tax Authority [Member]
Federal
State and Local Jurisdiction [Member]
State
Foreign Tax Authority [Member]
Foreign
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Income Tax Disclosure [Line Items]
Income Taxes
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Increase from change in the valuation allowance
Operating Loss Carryforwards
Gross NOL carryforwards
Percentage of taxable income limitation on an annual basis of net operating loss carryforwards having an indefinite carryforward period.
Operating Loss Carryforwards, Indefinite Carryforward Period, Percentage of Taxable Income Limitation on Annual Basis
Percentage of taxable income limitation on an annual basis
Maximum percentage of cumulative change in the ownership interest of significant stockholders affecting the amount of the NOL carryforwards and R&D tax credits that the Company may utilize.
Operating Loss Carryforwards, Limitations on Use Upon Cumulative Change in Ownership Interest of Significant Stockholders, Maximum Percentage
Maximum percentage of cumulative change in the ownership interest
Period considered for cumulative change in the ownership interest of significant stockholders affecting the amount of the NOL carryforwards and R&D tax credits that the Company may utilize.
Operating Loss Carryforwards, Limitations on Use Upon Cumulative Change in Ownership Interest of Significant Stockholders, Period
Period considered for cumulative change in the ownership interest
Period of amortization of research and experimental activities as per Tax Cuts and Jobs Act.
Tax Cuts and Jobs Act, Research and Experimental Activities, Amortization Period
Period of amortization of research and experimental activities
Deferred tax assets recognized for research and experimental activities as per Tax Cuts and Jobs Act.
Tax Cuts and Jobs Act, Research and Experimental Activities, Deferred Tax Asset
Deferred tax assets recognized for research and experimental activities
Percentage of valuation allowance on net deferred tax assets.
Percentage of Valuation Allowance on Net Deferred Tax Assets
Percentage of valuation allowance on net deferred tax assets
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Unrecognized tax benefits, if recognized, would impact the Company's effective tax rate
Unrecognized Tax Benefits, Interest on Income Taxes Accrued
Interest accrued
Unrecognized Tax Benefits, Income Tax Penalties Accrued
Penalties accrued
This member stands for first tranche of 2019 loan and security agreement.
Two Thousand Nineteen Loan And Security Agreement, Tranche One [Member]
First Tranche
Represents the information pertaining to Orchestra common stock.
Orchestra Common Stock [Member]
Orchestra common stock
Number of shares issued per share in case of Business Combination.
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Issued Per Share
Number of shares issued in Business combination
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares
Number of new shares issued for each existing shareholder